Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 18215977)

1.

Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.

Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA, McMillan F, King MS, Hanna GJ, Brun SC.

HIV Clin Trials. 2008 Jan-Feb;9(1):1-10. doi: 10.1310/hct0901-1.

PMID:
18215977
2.

Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.

Han Y, Li Y, Xie J, Qiu Z, Li Y, Song X, Zhu T, Li T.

PLoS One. 2015 Mar 30;10(3):e0120705. doi: 10.1371/journal.pone.0120705. eCollection 2015.

3.

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.

Gatell Artigas JM, Arribas López JR, Lázaro Y de Mercado P, Blasco Bravo AJ.

Enferm Infecc Microbiol Clin. 2015 Mar 3. pii: S0213-005X(15)00067-1. doi: 10.1016/j.eimc.2015.01.018. [Epub ahead of print]

PMID:
25749416
4.

Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.

Huang X, Xu Y, Yang Q, Chen J, Zhang T, Li Z, Guo C, Chen H, Wu H, Li N.

Sci Rep. 2015 Feb 23;5:8528. doi: 10.1038/srep08528.

5.

Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.

Farhoudi M, Khalili H, Karimzadeh I, Abbasian L.

Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):471-9. doi: 10.1517/17425255.2014.993606. Epub 2015 Jan 5.

PMID:
25557864
6.

Low Third-Trimester Serum Levels of Lamivudine/Zidovudine and Lopinavir/Ritonavir in an HIV-Infected Pregnant Woman with Gastric Bypass.

Michalik DE, Jackson-Alvarez JT, Flores R, Tolentino-Baldridge C, Batra JS.

J Int Assoc Provid AIDS Care. 2015 Mar;14(2):116-9. doi: 10.1177/2325957414555231. Epub 2014 Oct 31.

PMID:
25361558
7.

Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.

Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):128-35. doi: 10.1097/QAI.0000000000000281.

PMID:
25072616
9.

Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.

Podzamczer D, Imaz A, Perez I, Viciana P, Valencia E, Curto J, Martín T, Castaño M, Rojas J, Espinosa N, Moreno V, Asensi V, Iribarren JA, Clotet B, Force L, Bachiller P, Knobel H, López Bernaldo De Quirós JC, Blanco JR, Rozas N, Vergas J, Ocampo A, Camacho A, Flores J, Gomez-Sirvent JL; KIDAR Study Group.

J Antimicrob Chemother. 2014 Sep;69(9):2536-40. doi: 10.1093/jac/dku157. Epub 2014 May 15.

PMID:
24833755
10.

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.

Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ; GARDEL Study Group.

Lancet Infect Dis. 2014 Jul;14(7):572-80. doi: 10.1016/S1473-3099(14)70736-4. Epub 2014 Apr 27.

PMID:
24783988
11.

Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.

Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B, Rabie H, Wood R, Cox V, Vizcaya LS, Muchiri E, Davies MA; IeDEA Southern Africa Paediatric Collaboration.

Pediatr Infect Dis J. 2014 Jun;33(6):617-22. doi: 10.1097/INF.0000000000000222.

12.

Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.

Kang SJ, An JH, Kim J, Jang MO, Kim SE, Park KH, Jung SI, Jang HC.

Jpn J Infect Dis. 2013;66(4):317-9.

13.

Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.

Bernardino JI, Pulido F, Martinez E, Arrizabalaga J, Domingo P, Portilla J, Ocampo A, Muñoz J, Torres R, Arribas JR; GESIDA-6008-KRETA Study Group.

J Antimicrob Chemother. 2013 Jun;68(6):1373-81. doi: 10.1093/jac/dks540. Epub 2013 Feb 5.

14.

Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.

Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, Coovadia A, Abrams EJ, Kuhn L.

Arch Dis Child. 2013 Apr;98(4):258-64. doi: 10.1136/archdischild-2012-302633. Epub 2012 Dec 5.

PMID:
23220209
15.

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F.

HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23.

PMID:
23088336
16.

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.

Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group.

Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Erratum in: Antivir Ther. 2012;17(7):1389-90.

PMID:
23075703
17.

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, Pearce G.

Antivir Ther. 2012;17(6):1011-20. doi: 10.3851/IMP2305. Epub 2012 Aug 15.

PMID:
22910324
18.

Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.

Ramautarsing RA, van der Lugt J, Gorowara M, Sophonphan J, Ananworanich J, Lange JM, Burger DM, Phanuphak P, Ruxthungtham K, Avihingsanon A.

Antivir Ther. 2013;18(2):249-52. doi: 10.3851/IMP2324. Epub 2012 Aug 23.

PMID:
22908131
19.

A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.

Cooper C, la Porte C, Tossonian H, Sampalis J, Ackad N, Conway B.

HIV Clin Trials. 2012 Jul-Aug;13(4):179-88. doi: 10.1310/hct1304-179.

PMID:
22849960
20.

Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.

Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team.

PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk